Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis


So the reason that we did this study is
that although there’s been very significant advance in our management of
psoriasis in recent years with the introduction of biologic therapies to
manage patients with severe psoriasis it’s important that we understand
whether these work well across all sub-populations of patients depending on
demographics, disease severity and whether they’ve had previous treatment
before. So in this trial we use the new biologic called guselkumab
to ascertain whether it had produced significant benefits across
different patient populations and across different treatment regimens which they
may have received previously. So the way that we did this study
is that we used one of the new
anti-interleukin 23 biologics called guselkumab which has
shown very high efficacy and good safety profile in patients with severe
psoriasis and we pulled data from two large phase three studies called voyage
trials. We wanted to compare the efficacy of guselkumab against placebo
and against a commonly used anti tumor necrosis factor biologic called adalimumab and we subsetted the patients according to demographics and also
according to their response to therapy. Key findings of a study were that we found
high levels of efficacy of guselkumab gets compared with placebo adalimumab
across different patient subpopulations and different degrees of severity.
So at 16 weeks of treatment guselkumab was more effective than
placebo or adalimumab producing significant improvement in
psoriasis. Importantly at week 24 more patients have achieved almost
complete clearance or complete clearance with guselkumab as compared
with adalimumab or placebo. This was particularly true when compared with
adalimumab in patients who are overweight and that’s particularly
patients who are over hundred kilograms in weight. Also in patients who have
had several different biologic therapies previously. Why are the results of this
study relevant to dermatologists and also to their patients? With new biologic such as
guselkumab we’re now able to produce clearance or almost complete clearance in a
large number of patients receiving this particular biologic. What we’ve been
able to show in this particular trial is that this is true in subpopulations of
patients, patients who have previously been on other treatments and maybe
failed those and also in patients who are over a hundred kilograms in weight and it’s the heavier group which don’t tend to respond so well to other biologics

Leave a Reply

Your email address will not be published. Required fields are marked *